LifeMD 

LifeMD, Inc. is a telehealth company, which engages in offering portfolio of direct-to-patient products and services. It combines virtual medical treatment with prescription medications and over-the-counter products. The firm's network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the United States. The firm's brands include Shapiro, Rex, and Nava. The company was founded in 1987 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AGF Management reports stable performance and growth opportunities in Q1 2023

AGF Management delivered stable performance in Q1 2023 with positive net sales and a dividend increase.
While facing challenges in certain business segments, AGF's strong cash position and investment portfolio provide a solid foundation.
Opportunities lie in capital allocation strategies, growth initiatives, and enhancing performance in key business areas.
Overall, AGF's focus on shareholder returns and strategic investments positions the company for future growth and success.

LifeMD surpasses Q1 expectations, eyes growth amid challenges

LifeMD's Q1 2023 performance exceeded expectations, driven by strong revenue and EBITDA results.
The company's strategic initiatives, including debt financing and AI integration, position it for growth.
Challenges lie in maintaining growth momentum, managing costs, and optimizing EBITDA margins.
Opportunities in partnerships, telehealth, and patient value enhancement offer avenues for future growth.

LifeMD reports strong Q2 performance and raises revenue guidance

LifeMD's Q2 performance reflects operational strength, revenue growth, and strategic initiatives driving positive results and financial stability.
While facing challenges in adjusted EBITDA guidance due to investments, the company maintains a strong position with record revenues and subscriber growth.
Opportunities for growth and expansion exist through the weight management program, partnerships, and focus on existing health care businesses.

LifeMD reports record Q3 revenue and profitability, eyes growth opportunities

LifeMD's Q3 results reflect a successful quarter marked by strong revenue, profitability, and subscriber growth. The company's focus on strategic initiatives and positive outlook for 2024 indicate a promising future with plans to accelerate momentum and deliver impressive results.

LifeMD reports record 2023 performance, eyes growth in weight management

LifeMD's strong performance in 2023 sets the stage for continued growth and profitability. The company's strategic focus on diversification, market expansion, and cost management positions it well for future success. Challenges in subscriber numbers and commercial partnerships require attention, but overall, LifeMD is on a positive trajectory.

LifeMD excels in Q2 with telehealth growth, WorkSimpli rebounds

LifeMD demonstrated robust performance in Q2 2024, driven by the success of its core telehealth business and strategic initiatives.
While facing challenges, WorkSimpli is making progress towards regaining peak profitability by addressing competitive and executional issues.
Opportunities lie in expanding service offerings, enhancing collaborations, and leveraging upcoming launches to drive growth and profitability for LifeMD.
Strategic focus on innovation, efficiency, and market differentiation positions LifeMD well for sustained success and revenue growth in the future.

LifeMD reports robust Q3 results, eyes Medicare expansion for growth

LifeMD's Q3 performance reflects strong revenue growth, operational improvements, and strategic expansion initiatives.
The company's focus on telehealth, men's health, and work simplification businesses is driving positive results.
While facing challenges in scaling operations and market competition, LifeMD is well-positioned for continued growth.
Opportunities in Medicare expansion, program enhancements, and market partnerships offer avenues for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The firm combines virtual medical treatment with prescription medications and over-the-counter products. It operates through the Telehealth and WorkSimpli segments. The company was founded by Justin Schreiber on May 24, 1994 and is headquartered in New York, NY.

LifeMD reached positive operating cash flow for the first time during its fiscal 2023 second quarter. This boosted the telehealth company's cash and equivalents position and formed an inflection point for its investment pitch. WorkSimpli is experiencing material year-over-year growth and could exit LifeMD's fiscal 2024 with a $100 million revenue run rate.

LifeMD: I'm Buying The Commons And The 11.7% Yielding Preferreds

NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD) today announced that management will be participating in two upcoming investor conferences in September.

LifeMD to Participate in Two Investor Conferences in September

Enviri Corp

CarParts.com, Inc.

Primarily, one reason stands above all the others regarding the incentive behind stocks with insider buying: those who are closest to a particular business would only be buying shares if they believed the stock would rise higher. Otherwise, if they felt convinced that the business could tumble, they would probably exit their holdings.

Insiders Are Betting Big on These 3 Stocks Under $10

LifeMD is positioned for rapid growth with the introduction of a weight management program and partnerships with Nutrisystem and Medifast. The company has seen an increase in new client signups for its weight loss program, with a goal of reaching 400 per day by the end of 2023. LifeMD's revenue is expected to grow significantly, with a consensus forecast of $175 million for 2024, driven by the demand for GLP-1 prescriptions and partnerships in the weight loss industry.

LifeMD: A Derivative Beneficiary Of The Demand For Anti-Obesity Pharmaceuticals

LifeMD, Inc. (NASDAQ:LFMD ) Q2 2023 Earnings Call Transcript August 9, 2023 4:30 PM ET Company Participants Justin Schreiber - Chairman and Chief Executive Officer Marc Benathen - Chief Financial Officer Conference Call Participants David Larsen - BTIG, LLC Sarah James - Cantor Fitzgerald Operator Good afternoon. Thank you for joining us today to discuss the results for LifeMD's Second Quarter ended June 30, 2023, Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer; and Marc Benathen, Chief Financial Officer of LifeMD.

LifeMD, Inc. (LFMD) Q2 2023 Earnings Call Transcript

Revenue grew 18% year-over-year to a record $35.9 million; telehealth net revenues increased 11% versus the first quarter of 2023. Achieved positive free cash flow, ahead of guidance.

LifeMD Reports Second Quarter 2023 Results; Achieves Positive Free Cash Flow and Raises 2023 Revenue Guidance

NEW YORK, July 26, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended June 30, 2023 after the close of the U.S. financial markets on August 9, 2023 and will host a conference call beginning at 4:30 p.m. Eastern time.

LifeMD to Report Second Quarter 2023 Financial Results on August 9

Shares of telehealth platform LifeMD, Inc. have cratered 85% from their all-time high of February 2021, as profitability had been elusive. That said, the company's stock has more than tripled off its all-time low ($1.14) as it is poised to become cash flow positive. Trading at 0.85 times FY23E revenue that is projected to grow 22%, the recent insider buying merited a deeper dive.

LifeMD: Behind The Lazarus-Like Move

Proprietary platform enhancements elevate LifeMD's GLP-1 weight management program with best-in-class clinician-directed care and personalized guidance Proprietary platform enhancements elevate LifeMD's GLP-1 weight management program with best-in-class clinician-directed care and personalized guidance

LifeMD Elevates Successful GLP-1 Weight Management Program with Proprietary Platform Enhancements

LifeMD's year-to-date returns of 106% show a management turnaround, with the company aiming to reach cash flow breakeven by mid-2023. The telehealth market is forecasted to grow at a 35% compound annual growth rate from 2023, with LifeMD's portfolio of brands poised to benefit from this trend. LifeMD's first-quarter revenue grew by 13.8% year-over-year, with gross profit margin expanding to 87.28%, and net losses improving to $4 million.

LifeMD's Turnaround Shows Sign Of Life

NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of William (Will) J. Febbo, Chief Executive Officer and Director of OptimizeRx Corporation (Nasdaq: OPRX) to its Board of Directors. OptimizeRx is a leading provider of digital point-of-care technology solutions that help patients start and stay on therapy.

LifeMD Appoints William J. Febbo to its Board of Directors

New York, New York--(Newsfile Corp. - May 23, 2023) - LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced that LifeMD management will participate in the virtual June 1st Investor Summit. Event: June 1st Investor Summit Presentation: June 1, 2023 at 10:00 a.m.

LifeMD, Inc. to Present at the June 1st Virtual Investor Summit

LifeMD, Inc. (NASDAQ:LFMD ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants Justin Schreiber - Chairman and Chief Executive Officer Marc Benathen - Chief Financial Officer Conference Call Participants David Larsen - BTIG, LLC Operator Good morning. Thank you for joining us today to discuss the results for LifeMD's First Quarter ended March 31, 2023.

LifeMD, Inc. (LFMD) Q1 2023 Earnings Call Transcript

NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) --   LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the first quarter ended March 31, 2023. All figure comparisons are to the same year-ago quarter unless otherwise noted. Management will host a conference call today, May 12, 2023, at 8:30 a.m. Eastern Time to discuss the results. An updated corporate presentation was posted to https://ir.lifemd.com/#/ prior to market open.

LifeMD, Inc. Reports First Quarter 2023 Results; Record Revenues and Adjusted EBITDA

NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading provider of virtual primary care services, today announced that it has entered into an agreement to be the exclusive telehealth provider for HealthWarehouse.com, Inc. (OTC: HEWA).

LifeMD and HealthWarehouse.com Partner in Exclusive Telehealth Agreement

NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a rapidly growing direct-to-patient telehealth company, today announced that it will report its financial results for the first quarter ended March 31, 2023 before the market open on Friday, May 12, 2023. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30am Eastern Time.

LifeMD, Inc. to Announce First Quarter 2023 Financial Results on May 12, 2023

LifeMD's 18% year-to-date fall has extended the 2022 stock weakness to push the telehealth company to the lowest multiple amongst its peers. This was against fiscal 2022 fourth-quarter revenue that notched the company's first sequential revenue decline since the pandemic.

LifeMD: Bottom Fishing With Its Unrated High Yield Preferreds

NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading provider of virtual primary care services, today announced the launch of new membership plans that enable immediate access to best-in-class virtual care. LifeMD's new plans, powered by innovative features and enhancements to its proprietary app, expand care and provide patients with the most flexibility when seeking virtual treatment.

LifeMD Launches New Features and Membership Plans to Improve Patient Experience and Broaden Access to Healthcare

AGF Management Ltd (NASDAQ:LFMD ) Q1 2023 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants Jenny Quinn - VP, CAO & Interim CFO Kevin McCreadie - CEO, CIO & Director Judith Goldring - President, Head, Global Distribution & Director Conference Call Participants Gary Ho - Desjardins Securities Geoffrey Kwan - RBC Capital Markets Nikolaus Priebe - CIBC Tom MacKinnon - BMO Capital Markets Operator Ladies and gentlemen, thank you for standing by, and welcome to the First Quarter 2023 AGF Management Limited Earnings Conference Call. [Operator Instructions].

AGF Management Ltd (LFMD) Q1 2023 Earnings Call Transcript

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the fourth quarter and full year ended December 31, 2022. All figure comparisons are to the same year-ago quarter unless otherwise noted. Management will host a conference call today, March 22, 2023, at 4:30 p.m. Eastern Time to discuss the results. An updated corporate presentation and Q4 '22 supplemental presentation were posted to https://ir.lifemd.com/#/ following the market close.

LifeMD, Inc. Reports Fourth Quarter/ Full Year 2022 Results; Achieves Consolidated Adjusted EBITDA Profitability

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced that the Company closed on a new senior secured credit facility with Avenue Capital. The credit agreement, which matures on October 1, 2026, provides up to $40 million in total term loan capital including a first tranche of $15 million funded at closing, a second tranche of $5 million of committed capital and an additional accordion option to upsize the credit facility by an additional $20 million.

LifeMD, Inc. Announces Closing of New $40 Million Credit Facility

NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a rapidly growing direct-to-patient telehealth company, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2022 after the market close on Wednesday, March 22, 2023. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.

LifeMD, Inc. to Announce Fourth Quarter, Full Year 2022 Financial Results on March 22, 2023

NEW YORK, Feb. 10, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the appointment of Dr. Joan LaRovere to its Board of Directors. With Dr. LaRovere's appointment, LifeMD's Board will comprise nine directors, seven of whom are independent.

LifeMD Appoints Dr. Joan LaRovere to its Board of Directors

NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the appointment of Jessica Friedeman as Chief Marketing Officer. Friedeman succeeds Stefan Galluppi, who continues as LifeMD's Chief Innovation Officer.

LifeMD Appoints Jessica Friedeman as Chief Marketing Officer to Support the Company's Rapid Expansion into Virtual Primary Care

NEW YORK, Nov. 18, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced that LifeMD management will participate in the following upcoming conferences:

News for LifeMD Stock (LFMD)